- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01923103
Natural Disease Progress of Dupuytren Disease (DD)
Dupuytren disease (DD) is a progressive fibromatosis of the palmar fascias of the hand and fingers, which may lead to extension deficits of the fingers. The disease can be very disabling in moderate and severe cases, whereby performing normal daily activities can become very problematic. The aetiology and pathogenesis are not completely understood. There is a genetic disposition and it is influenced by environmental factors. The disease is especially prevalent in white males of Northern European descent above 50 years of age. There is paucity of knowledge about the natural progression of the disease. Several studies have been conducted on progression of disease and from these studies it becomes obvious that the disease is progressive over several years. However, in most studies only one moment of follow-up has taken place, so the course of the progression over time is unknown.
The aim of this study is to enhance our knowledge on the natural disease progression of DD at different stages.
Study Overview
Status
Conditions
Detailed Description
Objective:
- Primary objective: To study natural disease progress of Dupuytren Disease (DD) in different stages of disease in males and females above 18 years of age.
Secondary objectives:
- To study the effect of potential risk factors for DD on natural disease progress.
- To study at what stage of disease patients with DD experience problems in daily life.
- To study the incidence and course of recurrent disease. Primary Hypothesis: The natural course of disease is an exponential function of time.
- To study the intrarater reliability of the measurements
f. To determine whether the echogenicity of the nodules can predict progression g. To determine whether extension deficit measurements can be replaced by measurements of extension, and whether this will facilitate the statistical analysis h. To determine the association between passive and active measurements of extension and extension deficit, and to see whether active measurements can be derived from passive measurements and vice versa.
- Study design: The study is designed as a prospective observational pilot study with a follow-up of 10 years.
- Study population: Males and females above 18 years of age with all stages of primary Dupuytren's disease in at least one hand
- Main study parameters/endpoints: The natural course of progression of DD measured as the increase or decrease in size of nodules and cords in millimetres and/or increase of total passive extension deficit in degrees, from baseline to endpoint.
Secondary study parameters:
- Patient-reported hand function (Michigan Hand Outcomes Questionnaire (MHOQ), Patient-Rated Wrist/Hand Evaluation (PRWHE) and Unité Rhumatologique des Affections de la Main (URAM) scale
- incidence and course of recurrent disease
- disease activity (ultrasonography and tonometry)
- Procedure Patients visit the outpatient clinic every 6 months (first 5 years of follow-up) and later on every 12 months (last 5 years of follow-up) for an anamnestic interview, physical examination of the hands, ultrasonography, tonometry and for filling out the PROMs.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Groningen, Netherlands, 9700 RB
- University Medical Center Groningen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients (> 18 years of age) with primary Dupuytren's disease in all Tubiana stages
- Operated hands of patients with primary Dupuytren's disease on the contra lateral hand
Exclusion Criteria:
- Patients who are incapable of giving consent
- Patients who are not able or not willing to visit the UMCG for follow-up
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The course of DD: passive and active extension deficit and dimension of palpable nodules and cords
Time Frame: every 6-12 months
|
Active and passive extension deficit is measured with a goniometer at joint level Dimension of nodules and cords is measured using a tumorimeter
|
every 6-12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease activity: Echogenicity and nodule hardness
Time Frame: every 12 months, starting from 2016 (ultrasound) and 2018 (tonometry)
|
Activity of a nodule is determined by 1) echogenicity of the ultrasound image in sagittal and transversal plane, 2) hardness of the nodule determined by tonometry
|
every 12 months, starting from 2016 (ultrasound) and 2018 (tonometry)
|
Patient-reported hand function: MHQ, PRWHE and URAM
Time Frame: every 6-12 months
|
To study what problems patients with DD experience in daily life, PROMs are used.
MHQ and PRWHE in the first 2 years, URAM later on
|
every 6-12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Paul MN Werker, PhD, University Medical Center Groningen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Disease Attributes
- Joint Diseases
- Musculoskeletal Diseases
- Connective Tissue Diseases
- Muscular Diseases
- Neoplasms, Connective Tissue
- Neoplasms, Fibrous Tissue
- Fibroma
- Disease Progression
- Contracture
- Dupuytren Contracture
Other Study ID Numbers
- NDPDD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Disease Progression
-
IRCCS San RaffaeleRecruitingGynecologic Cancer | Radiotherapy Side Effect | Survivorship | Radiotherapy; Complications | Progression, Disease | Progression, ClinicalItaly
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Assiut UniversityNot yet recruiting
-
The Hong Kong Polytechnic UniversityAston University; Queensland University of Technology; Menicon Co., Ltd.Completed
-
Illinois College of OptometryUnknown
-
Grupo Hospital de MadridCompletedProgression Free SurvivalSpain
-
Central Hospital, Nancy, FranceCompleted
-
The Hong Kong Polytechnic UniversityMenicon Co., Ltd.Active, not recruitingMyopic ProgressionHong Kong
-
Peking UniversityCompletedProgression Free Survival of the TreatmentChina
-
The Hong Kong Polytechnic UniversityAston University; Queensland University of Technology; Menicon Co., Ltd.Completed